Tamoxifen and liver damage.
作者信息
Blackburn A M, Amiel S A, Millis R R, Rubens R D
出版信息
Br Med J (Clin Res Ed). 1984 Aug 4;289(6440):288. doi: 10.1136/bmj.289.6440.288.
Abstract
摘要
相似文献
1
Tamoxifen and liver damage.他莫昔芬与肝损伤。
Br Med J (Clin Res Ed). 1984 Aug 4;289(6440):288. doi: 10.1136/bmj.289.6440.288.
2
Benign hepatic cyst in a patient on antiestrogen therapy for metastatic breast cancer.一名接受抗雌激素治疗的转移性乳腺癌患者出现良性肝囊肿。
Cancer. 1982 Nov 1;50(9):1882-3. doi: 10.1002/1097-0142(19821101)50:9<1882::aid-cncr2820500938>3.0.co;2-f.
3
[Hepatitis during treatment with tamoxifen. Effects on the kinetics of epirubicin].[他莫昔芬治疗期间的肝炎。对表柔比星动力学的影响]
Therapie. 1989 Mar-Apr;44(2):151-2.
4
Tamoxifen-associated hepatocellular damage and agranulocytosis.他莫昔芬相关的肝细胞损伤和粒细胞缺乏症。
Lancet. 1992 Apr 11;339(8798):940. doi: 10.1016/0140-6736(92)90991-b.
5
Fatty liver and transaminase changes with adjuvant tamoxifen therapy.辅助性他莫昔芬治疗引起的脂肪肝和转氨酶变化。
Anticancer Drugs. 2006 Jul;17(6):709-13. doi: 10.1097/01.cad.0000215056.47695.92.
6
Tamoxifen-associated steatohepatitis--report of three cases.他莫昔芬相关性脂肪性肝炎——三例报告
J Hepatol. 1995 Jul;23(1):95-7. doi: 10.1016/0168-8278(95)80316-5.
7
Tamoxifen-induced hepatotoxicity.他莫昔芬诱导的肝毒性。
Indian J Cancer. 2011 Jul-Sep;48(3):385. doi: 10.4103/0019-509X.84935.
8
Tamoxifen-induced steatohepatitis.他莫昔芬诱导的脂肪性肝炎。
Ann Intern Med. 1995 Aug 1;123(3):236. doi: 10.7326/0003-4819-123-3-199508010-00018.
9
Tamoxifen-induced transient multifocal hepatic fatty infiltration.他莫昔芬诱导的短暂性多灶性肝脂肪浸润。
Am J Gastroenterol. 2000 Jan;95(1):277-9. doi: 10.1111/j.1572-0241.2000.01708.x.
10
Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.托瑞米芬和他莫昔芬对绝经后乳腺癌患者的雌激素样作用。
Breast Cancer Res Treat. 2003 Nov;82(2):103-11. doi: 10.1023/B:BREA.0000003957.54851.11.
引用本文的文献
1
Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice.破坏 DREAM 转录抑制复合物可诱导小鼠载脂蛋白过度表达和全身淀粉样变性。
J Clin Invest. 2021 Feb 15;131(4). doi: 10.1172/JCI140903.
2
A case-control study of non-alcoholic fatty liver disease in breast cancer.乳腺癌中非酒精性脂肪性肝病的病例对照研究。
Med Oncol. 2007;24(4):367-71. doi: 10.1007/s12032-007-0034-8.
3
Tamoxifen in postmenopausal women a safety perspective.
Drugs Aging. 1996 May;8(5):329-37. doi: 10.2165/00002512-199608050-00002.
4
Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy.
Dig Dis Sci. 1995 Dec;40(12):2602-7. doi: 10.1007/BF02220448.
5
A risk-benefit assessment of tamoxifen therapy.他莫昔芬治疗的风险效益评估。
Drug Saf. 1993 May;8(5):381-97. doi: 10.2165/00002018-199308050-00005.
6
Effect of toremifene on antipyrine elimination in the isolated perfused rat liver.托瑞米芬对离体灌注大鼠肝脏中安替比林消除的影响。
Cancer Chemother Pharmacol. 1993;31(4):319-23. doi: 10.1007/BF00685678.
7
Phase I trial of droloxifene in patients with metastatic breast cancer.屈洛昔芬用于转移性乳腺癌患者的I期试验。
Cancer Chemother Pharmacol. 1994;33(4):313-6. doi: 10.1007/BF00685906.
8
Tamoxifen in the prevention of breast cancer. Are the risks likely to outweigh the benefits?他莫昔芬用于预防乳腺癌。风险是否可能超过益处？
Drug Saf. 1994 Jan;10(1):1-4. doi: 10.2165/00002018-199410010-00001.
9
Drug-induced cholestasis.药物性胆汁淤积
Med Toxicol. 1987 Mar-Apr;2(2):112-60. doi: 10.1007/BF03260010.
10
A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.一种新型三苯乙烯化合物，Fc - 1157a。II. 抗肿瘤作用。
Cancer Chemother Pharmacol. 1986;17(2):109-13. doi: 10.1007/BF00306737.
本文引用的文献
1
Bone 'flare,' hypercalcemia, and jaundice after tamoxifen therapy.
Arch Intern Med. 1981 Aug;141(9):1240.
2
Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels.乳腺癌的抗雌激素治疗：两种剂量水平他莫昔芬的试验
Br Med J. 1973 Jan 6;1(5844):13-4. doi: 10.1136/bmj.1.5844.13.
3
Safety of tamoxifen.他莫昔芬的安全性。
Lancet. 1978 Jan 14;1(8055):105. doi: 10.1016/s0140-6736(78)90053-3.
Zotero 插件